Turkey Tail: PSK, PSP and Human Research

What is turkey tail mushroom?

Turkey tail is Trametes versicolor, also called Coriolus versicolor, a wood-growing bracket fungus. Its brown and tan rings resemble a turkey's tail. Supplements use the visible fruiting body, cultivated mycelium—the growing thread network—or extracts made from them.

PSK, also called krestin, is a proprietary protein-bound carbohydrate mixture made from cultured mycelium. PSP is a different extract, developed in China. A label saying “turkey tail polysaccharides” does not identify either preparation. The National Cancer Institute's account^[1] distinguishes these materials.

Traditional uses and modern preparations

The NCI historical account^[1] records Chinese use for pulmonary diseases and the names Yun Zhi and Japanese Kawaratake. These describe medicinal traditions, not demonstrated treatment outcomes. Modern Japanese PSK developed into a purified hot-water mycelial preparation used alongside cancer treatment from the mid-1970s. Chinese PSP is another preparation with different composition.

The transition changed both the product and the question: traditional treatment of respiratory complaints became research on defined extracts, immune measurements and survival during cancer care.

Why do people take turkey tail?

Claimed benefit	Dose / form studied	Research verdict	Evidence strength
Improve outcomes after colorectal cancer surgery	PSK, often 3 g/day, alongside specified older chemotherapy	Some disease-free and pooled survival findings are favorable; individual trials and treatment comparisons differ.	Limited
Improve outcomes after stomach-cancer surgery	Standardized PSK added to chemotherapy	An older trial reported better survival; a separate pooled review has an unresolved treatment-name discrepancy.	Review pending
Reduce chemotherapy side effects	PSK added to colorectal cancer treatment	The review found the evidence too uncertain to establish a reliable reduction.	Insufficient
Change immune measurements after breast-cancer radiotherapy	Freeze-dried mycelial powder, 3–9 g/day for six weeks	Preliminary blood-cell findings from nine completers without placebo.	Limited
Change gut bacteria	A named PSP extract in healthy volunteers	Microbial composition changed; improvement in digestive symptoms was not established.	Review pending
Improve vaccine response	Turkey tail plus another fungus, taken for four days	Small subgroup findings and mixed antibody comparisons; no turkey-tail-alone result.	Review pending
Prevent cancer or replace treatment	No established retail regimen	The reviewed treatment studies do not answer either question.	Insufficient

In cancer care, the relevant decision concerns a named preparation alongside a particular treatment plan. That is a discussion for the oncology team, not a reason to substitute a retail mushroom capsule for prescribed treatment.

How much was studied?

Some postoperative trials used 3 g/day of PSK, for one or two years alongside chemotherapy. The smaller breast-cancer study used 3, 6 or 9 g/day of a different mycelial powder for six weeks. These amounts belong to different preparations and treatment settings; there is no established general-wellness serving from these trials.

What should a label tell you?

The species, starting material and preparation identify what is in the product. Fruiting-body powder, mycelial powder, PSK and PSP are different mixtures. A broad “polysaccharide” percentage or a 10:1 extraction ratio does not show that a product matches PSK or PSP.

Preparation	Human research discussed here	What remains different
Proprietary PSK/Krestin	Added to particular Japanese postoperative chemotherapy regimens	Findings depend on the cancer, treatment and outcome.
Named PSP extract	Lung-cancer and healthy-volunteer microbiome studies	PSP is not PSK; these studies answer different clinical questions.
Freeze-dried mycelial powder	Small post-radiotherapy safety/immune study	This was not a recurrence or survival trial.
Fruiting-body powder, tea or generic extract	No matching clinical-outcome regimen established in the reviewed sources	The species name alone cannot establish equivalence to a medicinal preparation.

For a multi-mushroom blend, the total weight does not reveal each ingredient's amount. Studies of a combination also cannot tell us which ingredient produced a result.

Drawbacks and side effects

Potential drawback	When / who it affects	Research evidence	Practical implication
Uncertain compatibility with treatment	Cancer treatment or immune-suppressing medicines	Preparation and treatment context vary.	Review the exact product with the treating team.
Adverse symptoms	Users of studied powders or different extracts	Small studies cannot estimate uncommon harms; the breast-cancer study reported several events with uncertain attribution.	Report new symptoms and disclose all ingredients.
Replacing effective care	Cancer patients	Favorable evidence concerns added-to-treatment use.	Continue prescribed cancer care.

The 2012 dose study^[2] recorded nine adverse events among nine completers, including a severe anxiety attack. Its table called that event possibly related, while the narrative called it likely unrelated. That disagreement prevents a simple “no side effects” description and does not prove the powder caused the event.

Nor is fewer chemotherapy side effects established. The 2022 Cochrane review^[3] found uncertain effects on withdrawals, nausea, diarrhea, fatigue and mouth disorders. A favorable estimate for low neutrophil counts—a shortage of infection-fighting blood cells—was still rated very low certainty by the reviewers.

What have PSK cancer trials found?

Stomach cancer: a favorable older trial with unresolved source questions

A 1994 Japanese trial^[4] randomized 262 people after curative stomach-cancer surgery. Both groups received mitomycin and oral fluorouracil; one also received PSK. Overall survival measures who is still alive; disease-free survival also counts whether cancer has returned. After at least five years, survival was 73.0% with PSK versus 60.0% without it, and disease-free survival was 70.7% versus 59.4%. The reported differences were statistically significant.

A 2007 pooled review^[5] uses the names PSK and OK-432 as though they identify the same treatment. That unresolved identity discrepancy prevents treating its pooled estimate as confirmed evidence for a generic turkey-tail supplement.

An observational Taiwan study^[6] found longer survival among patients with at least one PSK prescription after surgery and chemotherapy. The adjusted death-rate estimate favored PSK, but treatment was not randomly assigned, chemotherapy differed between groups and a prescription did not establish a uniform dose or duration. This association is a different kind of evidence from the randomized trial.

Colorectal cancer: positive findings and a negative comparison

The Ohwada trial^[7] enrolled 207 patients after colorectal surgery and analyzed 205. PSK 3 g/day plus oral tegafur/uracil, after mitomycin, was compared with the same chemotherapy without PSK for up to two years. Five-year disease-free survival was 73.0% versus 58.8%. Overall survival was 81.8% versus 72.1%, but the statistical analysis could not rule out chance as an explanation for that difference.

A published critique^[8] questioned the chemotherapy control, rectal-cancer treatment and unusually poor control-group outcomes. The authors' reply^[9] supplied further analyses, including a rectal-cancer subgroup whose disease-free comparison was not significant.

The later JFMC 38 trial^[10] asked a different question: one year of tegafur/uracil plus PSK versus surgery alone for stage II rectal cancer. It registered 111 patients and analyzed 106. Five-year disease-free survival was 65.1% with the combination versus 77.2% with surgery alone, without a statistically significant difference. Because it had no chemotherapy-only arm, it cannot isolate PSK's contribution.

The Cochrane review^[3] reported a small five-year survival advantage across three studies and 1,094 patients, but rated the evidence low certainty. The older chemotherapy and trial limitations remain relevant. Another meta-analysis uses the same participant total; it is not an additional 1,094 independent patients.

PSP in lung cancer is a separate question

A 28-day placebo-controlled study^[11] enrolled 68 patients, 34 per arm, after conventional treatment for advanced non-small-cell lung cancer. Fewer participants withdrew because of progression: 5.9% versus 23.5%. The evaluable PSP recipients did not improve in lung-cancer-related symptoms. The abstract also described improved blood-cell, antibody and body-fat measurements within the PSP group, without providing clear between-group estimates for those outcomes. The accessible abstract does not supply a usable dose, and short-term progression-related withdrawal is not a demonstrated survival benefit.

What did the small post-radiotherapy study show?

The 2012 phase I study^[2] enrolled 11 women after breast-cancer radiotherapy; nine completed it. Three participants at each amount took 3, 6 or 9 g/day for six weeks. The preparation was freeze-dried mycelial powder supplied by Fungi Perfecti, in 500 mg capsules.

Researchers observed different counts of CD8-positive T cells—immune cells that can kill infected or abnormal cells—across the tiny dose groups over weeks two to six. Some comparisons also used an earlier untreated observational group. Without a randomized placebo group, these findings cannot reliably separate supplementation from recovery after radiotherapy.

PSP and the gut microbiome

A 2014 randomized study^[12] reported 24 healthy volunteers assigned to PSP, amoxicillin or no treatment; 22 completed. Its methods describe a named PSP product at 1,200 mg three times daily for 14 days, while stool sampling continued across eight weeks.

PSP changed the composition of gut bacteria, but stable differences between individuals remained larger than the treatment effects. This supports further study of how the extract interacts with gut microbes. It does not establish relief of constipation, diarrhea or another digestive symptom.

What did the vaccine-combination trial find?

A 2026 vaccine-adjunct trial^[13] randomized 90 adults to turkey tail plus Fomitopsis officinalis mycelium or rice placebo: 12 g/day for four days around COVID-19 vaccination. Everyone completed the 14-day safety period; 17 missed later follow-up.

Researchers classified prior exposure mainly from antibodies indicating earlier infection or vaccination. Selected days showed fewer side effects with the mixture in the subgroup classified as having no prior exposure, but the overall tests for side-effect count and severity were not significant.

Antibody changes over time differed significantly when treatment and prior exposure were considered together. However, separating the prior-exposure groups and comparing mixture against placebo within each did not show a significant difference in their antibody trajectories. The reported longer-lasting response came from changes within one subgroup, rather than a clear advantage over placebo. Five antibody outliers were excluded. The manufacturer supplied products, contributed funding and had coauthors. Infection prevention was not measured, and the mixture cannot isolate turkey tail's effect.

HPV research: oral infection and vaginal gels

A preliminary oral-HPV report^[14] identified 61 HPV-positive participants among 472 people screened. Forty-one received turkey tail plus reishi and twenty received a different mushroom, Laetiporus sulphureus. Reported clearance after two months was 88% versus 5%, but the available abstract does not establish the dose or administration route clearly enough for a supplement recommendation. Separately, vaginal-gel studies concern multicomponent local treatment.

Exercise research with a mushroom blend

A small exercise study^[15] included turkey tail in a six-mushroom blend. As discussed in the Cordyceps research account, the one-week comparisons were nonsignificant; an exploratory three-week subset showed improved maximum oxygen uptake. The study did not disclose a separate turkey-tail amount or isolate its contribution.

Bottom line

Turkey tail research extends from historical pulmonary use to distinct PSK, PSP and whole-mycelium preparations. Some older postoperative PSK trials reported favorable outcomes, alongside contrary comparisons, methodological criticism and uncertainty about current treatment relevance. PSP and mushroom mixtures have additional preliminary findings, but these do not create one proven general-wellness regimen.

The useful comparison is the specific preparation, the measured outcome and the treatment setting. For cancer care, that means discussing the exact product with the oncology team.

Help us improve this article

Spotted an error or found a source we should consider? Tell us which part of this article needs another look and include a link if you have one. Please leave out personal health details and lab results; we can’t answer individual medical questions.